Lysipressin acetate
Based on 2 publication(s) in Google Scholar
Lysipressin acetate (Lysine vasopressin acetate; [Lys8]-Vasopressin acetate) is a neurohypophyseal nonapeptide with dual cardiovascular regulatory activities of peripheral pressor action and central hypotensive action, and it also regulates pain perception in the body. Lysipressin acetate is an Oxytocin Receptor agonist, with a Ki value of 10.2 nM for porcine OT receptor. Lysipressin acetate stimulates contraction of rabbit bladder smooth muscle via V1-vasopressin receptor. The central hypotensive effect of Lysipressin acetate depends on the sympathetic tone pathway. Lysipressin acetate dose-dependently prolongs tail-flick latency in rats, producing a stable central antinociceptive effect. Lysipressin acetate can be used in studies related to cardiovascular regulation, hypertension and pain.
For research use only. We do not sell to patients.
- Purity: 99.81%
- CAS No.: 83968-49-4
- Formula: C48H69N13O14S2
- Molecular Weight:1116.27
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Peptide Library
HY-L105
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Lysipressin acetate
MoreAll Endogenous Metabolite Isoforms
MoreAll Vasopressin Receptor Isoforms
More
Biological Activity
Lysipressin (LVP) acetate enhances the contractile capacity of uterine muscle strips from luteal-phase and prepartum pigs in a dose-dependent manner by activating oxytocin receptors, with EC50 values of 0.392 μM and 0.223 μM, respectively; it also increases intracellular Ca2+ concentrations in prepartum porcine uterine myocytes, with an EC50 of 28.2 nM[1].
Lysipressin acetate dose-dependently displaces [3H]oxytocin binding sites on myometrial membranes of luteal-phase pigs, with a Ki value of 10.2 nM, indicating its high affinity for oxytocin receptors[1].
Lysipressin (LVP) acetate stimulates the contraction of bladder smooth muscle from male New Zealand white rabbits in vitro, with a mean pD2 value of 8.4[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Lysipressin (1.0-10.0 μ/kg; intravenous injection; single 5-second injection; intracisternal administration; single 5-second injection) acetate loses central hypotensive activity in anesthetized dogs after Guanethidine (HY-B1251) pretreatment, whereas its peripheral vasopressor effect stays unaltered[3].
Lysipressin (150-500 ng; intracerebroventricular injection; single administration) acetate produces significant, dose-dependent analgesic effects in the radiant heat tail-flick test[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 83968-49-4
-
Appearance Solid
-
Molecular Weight 1116.27
-
Formula C48H69N13O14S2
-
Color White to off-white
-
Synonyms
Lysine vasopressin acetate; [Lys8]-Vasopressin acetate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : ≥ 100 mg/mL (89.58 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yu H, et al. Lysine Vasopressin-Induced Increases in Porcine Myometrial Contractility and Intracellular Ca²⁺ Concentrations of Myometrial Cells: Involvement of Oxytocin Receptors. Biology of Reproduction, 1995, 52: 584-590. [Content Brief]
[2]. Crankshaw D, et al. [Arg8]vasopressin-induced contractions of rabbit urinary bladder smooth muscle. European journal of pharmacology. 1989 Dec 07;173(2-3):183-8. [Content Brief]
[3]. Tran LD, et al. Effects of lysine-vasopressin and oxytocin on central cardiovascular control. British journal of pharmacology. 1982 Sep;77(1):69-73. [Content Brief]
[4]. Kordower JH, et al. Central antinociceptive effects of lysine-vasopressin and an analogue. Peptides. 1982;3(4):613-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8958 mL | 4.4792 mL | 8.9584 mL | 22.3960 mL |
| 5 mM | 0.1792 mL | 0.8958 mL | 1.7917 mL | 4.4792 mL | |
| 10 mM | 0.0896 mL | 0.4479 mL | 0.8958 mL | 2.2396 mL | |
| 15 mM | 0.0597 mL | 0.2986 mL | 0.5972 mL | 1.4931 mL | |
| 20 mM | 0.0448 mL | 0.2240 mL | 0.4479 mL | 1.1198 mL | |
| 25 mM | 0.0358 mL | 0.1792 mL | 0.3583 mL | 0.8958 mL | |
| 30 mM | 0.0299 mL | 0.1493 mL | 0.2986 mL | 0.7465 mL | |
| 40 mM | 0.0224 mL | 0.1120 mL | 0.2240 mL | 0.5599 mL | |
| 50 mM | 0.0179 mL | 0.0896 mL | 0.1792 mL | 0.4479 mL | |
| 60 mM | 0.0149 mL | 0.0747 mL | 0.1493 mL | 0.3733 mL | |
| 80 mM | 0.0112 mL | 0.0560 mL | 0.1120 mL | 0.2800 mL |
Lysipressin acetate Related Classifications
HY-P0004A Related Classifications
Powered by Bioz
- Lysipressin
- 83968-49-4
- Lysine vasopressin
- [Lys8]-Vasopressin
- Endogenous Metabolite
- Oxytocin Receptor
- Vasopressin Receptor
- V1-vasopressin receptor
- porcine myometrial strips
- oxytocin (OT) receptor
- rabbit urinary bladder smooth muscle
- rat tail-flick latencies
- porcine myometrial membrane
- prepartum porcine myometrial cells
- porcine OT receptor
- male New Zealand white rabbit urinary bladder smooth muscle
- anesthetized dogs
- Inhibitor
- inhibitor
- inhibit